文献速递艾滋病与性传播感染

重组人乳铁蛋白对HIV感染者免疫激活与肠道微生物组的影响

The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy.
PubMed 文献 · J Infect Dis · 2019-01-01

一项随机安慰剂对照交叉临床试验纳入54例病毒抑制的HIV感染者,评估口服重组人乳铁蛋白的安全性及其对炎症、免疫激活和肠道微生物组的影响。中位年龄51岁,中位CD4+细胞计数651/µL。结果显示rh-乳铁蛋白安全且耐受性与安慰剂无差异,但未显著降低血浆IL-6、D-二聚体水平,也未改善单核细胞/T细胞激活、黏膜完整性或肠道菌群多样性。

要点

  • 口服rh-乳铁蛋白在病毒抑制的HIV感染者中安全性良好,不良事件与安慰剂无差异。
  • rh-乳铁蛋白未显著降低血浆IL-6或D-二聚体水平。
  • 未观察到对免疫激活、黏膜完整性或肠道菌群多样性的显著改善。

核心结论

  • 口服重组人乳铁蛋白在病毒抑制的HIV感染者中安全,但未能降低炎症和免疫激活。

研究设计与样本

  • 随机安慰剂对照交叉临床试验,纳入54例病毒抑制的HIV感染者,中位年龄51岁,中位CD4+细胞计数651/µL,注册号NCT01830595。

主要发现

  • rh-乳铁蛋白与安慰剂在依从性和不良事件方面无差异。
  • 对血浆白细胞介素-6或D-二聚体水平无显著影响。
  • 对单核细胞/T细胞激活、黏膜完整性或肠道微生物群多样性无显著影响。

临床怎么用

  • 现有证据不支持用口服rh-乳铁蛋白降低病毒抑制HIV感染者的炎症或免疫激活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/µL. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation. Clinical Trials Registration: NCT01830595.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sortino O, Hullsiek KH, Richards E, et al. The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy. J Infect Dis. 2019. PMID: 30721997. doi:10.1093/infdis/jiz042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。